Images in Pulmonary MedicineClinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2Barkas, Fotios MSc, PhD*; Liontos, Angelos MD*; Svarna, Evgenia MD†; Tsili, Athina MD, PhD†; Christaki, Marianna MD*; Rapti, Iro MD*; Argyropoulou, Maria I. MD, PhD†; Milionis, Haralampos MD, PhD*Author Information Departments of *Internal Medicine †Clinical Radiology and Imaging, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece Disclosure: The authors declare that they have no conflicts of interest. Address correspondence to: Haralampos Milionis, MD, PhD, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece. E-mail: [email protected]. Clinical Pulmonary Medicine: September 2020 - Volume 27 - Issue 5 - p 154-156 doi: 10.1097/CPM.0000000000000375 Buy Metrics Abstract Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting. We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms. Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.